Analysts’ Ratings for FibroGen and Its Peers in April 2018
FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease. The company has adopted a global approach to the development and commercialization of its product candidates.